Spots Global Cancer Trial Database for giant cell glioblastoma
Every month we try and update this database with for giant cell glioblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | NCT01480479 | Glioblastoma Small Cell Glio... Giant Cell Glio... Gliosarcoma Glioblastoma Wi... | Rindopepimut (C... Temozolomide KLH | 18 Years - | Celldex Therapeutics | |
| Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM | NCT00943462 | Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... | External-beam r... Temozolomide | 18 Years - 70 Years | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | NCT01609790 | Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Recurrent Brain... Recurrent Gliob... | Bevacizumab Laboratory Biom... Pharmacological... Placebo Adminis... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | NCT01957956 | Giant Cell Glio... Glioblastoma Gliosarcoma | Laboratory Biom... Malignant Gliom... Temozolomide | 18 Years - | Mayo Clinic | |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | NCT03014804 | Giant Cell Glio... Gliosarcoma Oligodendroglio... Recurrent Gliob... Small Cell Glio... | autologous dend... Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | NCT05218408 | Astrocytoma, Gr... Glioblastoma Giant Cell Glio... Glioblastoma Mu... | CYNK-001 system... | 18 Years - | Celularity Incorporated | |
| Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | NCT01082926 | Anaplastic Astr... Anaplastic Epen... Anaplastic Meni... Anaplastic Olig... Brain Stem Glio... Ependymoblastom... Giant Cell Glio... Glioblastoma Gliosarcoma Grade III Menin... Meningeal Heman... Mixed Glioma Pineal Gland As... Brain Tumor | therapeutic all... aldesleukin laboratory biom... positron emissi... | 18 Years - 70 Years | City of Hope Medical Center | |
| Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | NCT01149850 | Giant Cell Glio... Glioblastoma Gliosarcoma | bevacizumab temozolomide laboratory biom... immunohistochem... microarray anal... DNA methylation... | 70 Years - | Jonsson Comprehensive Cancer Center | |
| Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | NCT01095094 | Brain Tumor Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Brain Stem Glio... Giant Cell Glio... Glioblastoma Gliosarcoma Mixed Glioma | ritonavir lopinavir | 18 Years - | Case Comprehensive Cancer Center | |
| Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | NCT02709226 | Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... Gliosarcoma | Radiation | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201 | Anaplastic Astr... Brain Stem Glio... Childhood Mixed... Fibrillary Astr... Giant Cell Glio... Glioblastoma Gliosarcoma Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Pharmacological... Temozolomide Veliparib | - 21 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Recurrent Glioblastoma | NCT03360708 | Giant Cell Glio... Recurrent Gliob... Recurrent Glios... | Laboratory Biom... Malignant Gliom... | 18 Years - | Mayo Clinic | |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | NCT03014804 | Giant Cell Glio... Gliosarcoma Oligodendroglio... Recurrent Gliob... Small Cell Glio... | autologous dend... Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | NCT01149850 | Giant Cell Glio... Glioblastoma Gliosarcoma | bevacizumab temozolomide laboratory biom... immunohistochem... microarray anal... DNA methylation... | 70 Years - | Jonsson Comprehensive Cancer Center | |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | NCT04489420 | Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... Cyclophosphamid... Immunosuppressi... Immunologic Fac... Physiological E... Molecular Mecha... Antiviral Agent... Anti-infective ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... | CYNK001-IV CYNK001-IT | 18 Years - | Celularity Incorporated | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201 | Anaplastic Astr... Brain Stem Glio... Childhood Mixed... Fibrillary Astr... Giant Cell Glio... Glioblastoma Gliosarcoma Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Pharmacological... Temozolomide Veliparib | - 21 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Recurrent Glioblastoma | NCT03360708 | Giant Cell Glio... Recurrent Gliob... Recurrent Glios... | Laboratory Biom... Malignant Gliom... | 18 Years - | Mayo Clinic | |
| DC Migration Study for Newly-Diagnosed GBM | NCT02366728 | Glioblastoma Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... | Unpulsed DCs Td Human CMV pp65-... 111In-labeled D... Temozolomide Saline Basiliximab | 18 Years - 80 Years | Duke University | |
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | NCT01836549 | Anaplastic Astr... Anaplastic Epen... Astrocytoma, Gr... Ependymoma Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Brainstem Tumor... | imetelstat sodi... | 12 Months - 21 Years | Pediatric Brain Tumor Consortium | |
| Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | NCT00960492 | Glioblastoma Giant Cell Glio... Gliosarcoma | XL184 temozolomide temozolomide Radiation Thera... temozolomide | 18 Years - | Exelixis | |
| Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | NCT03027388 | Astrocytoma, Gr... Glioblastoma Mu... Giant Cell Glio... Glioma Oligodendroglio... | LB-100 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | NCT01498328 | Glioblastoma Small Cell Glio... Giant Cell Glio... Gliosarcoma Glioblastoma Wi... Recurrent Gliob... Relapsed Gliobl... | Bevacizumab Rindopepimut (C... KLH | 18 Years - | Celldex Therapeutics | |
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | NCT01836549 | Anaplastic Astr... Anaplastic Epen... Astrocytoma, Gr... Ependymoma Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Brainstem Tumor... | imetelstat sodi... | 12 Months - 21 Years | Pediatric Brain Tumor Consortium | |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | NCT01609790 | Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Recurrent Brain... Recurrent Gliob... | Bevacizumab Laboratory Biom... Pharmacological... Placebo Adminis... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | NCT05218408 | Astrocytoma, Gr... Glioblastoma Giant Cell Glio... Glioblastoma Mu... | CYNK-001 system... | 18 Years - | Celularity Incorporated | |
| Vaccine Therapy in Treating Patients With Recurrent Glioblastoma | NCT03360708 | Giant Cell Glio... Recurrent Gliob... Recurrent Glios... | Laboratory Biom... Malignant Gliom... | 18 Years - | Mayo Clinic | |
| A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | NCT01498328 | Glioblastoma Small Cell Glio... Giant Cell Glio... Gliosarcoma Glioblastoma Wi... Recurrent Gliob... Relapsed Gliobl... | Bevacizumab Rindopepimut (C... KLH | 18 Years - | Celldex Therapeutics | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201 | Anaplastic Astr... Brain Stem Glio... Childhood Mixed... Fibrillary Astr... Giant Cell Glio... Glioblastoma Gliosarcoma Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Pharmacological... Temozolomide Veliparib | - 21 Years | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
